Highlights:

• Liontown advanced after outlining FY27 growth plans and expansion milestones at Diggers & Dealers on 3 August 2026.
• PLS confirmed the timing of its FY26 results and investor webcast on 6 August 2026.
• Telix notified investors of its H1 2026 results release and webcast scheduled following its announcement on 31 July 2026.

Lithium and healthcare stocks emerged among the ASX's strongest performers, with Liontown Limited (ASX: LTR) climbing 9.49%, PLS Group Limited (ASX: PLS) gaining 7.09%, and Telix Pharmaceuticals Limited (ASX: TLX) rising 7.18%. While the companies released different types of announcements, investors responded positively to Liontown's operational update, PLS's upcoming earnings catalyst and Telix's approaching half-year results, reflecting renewed optimism across the mining and healthcare sectors.

Liontown Highlights Expansion-Focused FY27 Strategy

At the Diggers & Dealers Mining Forum presentation released on 3 August 2026, Liontown reaffirmed that its Kathleen Valley operation remains on track to achieve a 2.8 Mtpa run rate by the end of FY27. Management highlighted increasing underground development, additional mining equipment, expansion-ready infrastructure and a fully funded capital program supported by AU$561 million in cash at 30 June 2026. The company also maintained FY27 production guidance of 390,000–440,000 dry metric tonnes of spodumene concentrate while continuing early works for future expansion.

PLS Prepares Investors for FY26 Results

PLS announced on 6 August 2026 that it will release its FY26 full-year results on 24 August 2026, accompanied by an investor webcast and conference call. The company invited retail and institutional investors to participate in the presentation, which will provide further insight into its operational and financial performance following another year of activity across its Pilgangoora Operation and broader lithium portfolio.

Telix Sets the Stage for Half-Year Results

Meanwhile, Telix Pharmaceuticals informed the market on 31 July 2026 that it will announce its H1 2026 financial results on 20 August 2026, followed by an investor webcast and conference call. As a commercial-stage radiopharmaceutical company with an expanding oncology portfolio, investors are expected to closely monitor the upcoming update for further progress across its commercial products and late-stage therapeutic pipeline.

Outlook

With Liontown progressing its operational expansion, PLS approaching a key earnings milestone and Telix preparing to unveil its half-year financial performance, investors have multiple near-term catalysts to watch. As reporting season gathers pace, fresh operational and financial updates could continue driving sentiment toward these ASX-listed companies.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au